Sullivan & Cromwell LLP Logo
  • Home
  • Lawyers
  • Practices
  • Insights
  • About
  • Careers
  • Alumni
  • Twitter icon
  • LinkedIn icon
  •  icon
  • Podcasts icon
© 2025 Sullivan & Cromwell LLP
    • Home
    • Lawyers
    • Practices
    • Insights
    • About
    • Careers
    • Alumni
    Home /  About /  News And Events /  Client Highlights
    Client Highlights

    S&C Is U.S. Counsel to Takeda Pharmaceutical on U.S. Stock Listing and Historic Debt Offerings

    • Our Lawyers
    • Related Practices
    January 22, 2019

    When Japan’s Takeda Pharmaceutical Company Limited completed its approximately $62 billion acquisition of Shire PLC on January 8, 2019, Sullivan & Cromwell played a key role as Takeda’s U.S. counsel. The deal vaults Takeda into the top 10 pharmaceutical companies globally by revenue, and is the largest-ever acquisition of a foreign firm by a Japanese company, more than double the previous largest Japanese company acquisition.

    As U.S. counsel, S&C assisted Takeda in the filing of a registration statement with the Securities and Exchange Commission and in its listing on the New York Stock Exchange (NYSE), as well as in other SEC and U.S. law-related matters in connection with the acquisition. This follows S&C’s representation of Takeda in its debt offerings in November, including euro-denominated notes, which, at a total aggregate principal amount of €7.5 billion, was the largest debut euro-denominated unsecured bond offering in history, and a dollar-denominated note offering, which, at a total aggregate principal amount of $4.5 billion, was also the largest dollar-denominated bond offering by a Japanese issuer in history.

    The multi-disciplinary, cross-border S&C team acting for Takeda included Keiji Hatano and Nirav Mehta in Tokyo and Cathy Clarkin in New York.

    Takeda is known for its expertise in drugs aimed at the oncology, gastroenterology and neuroscience markets. The Shire acquisition is an important strategic move to expand Takeda’s sales for drugs targeted to rare diseases, which are Shire’s strength, and to increase sales in the U.S. market. Following the deal, the United States will account for about half of Takeda’s revenue.

    The deal also speaks to a broader trend in Japanese M&A, which has seen Japanese corporations turn increasingly to overseas acquisitions. In December, a MarketWatch article indicated that Japanese companies were involved in 621 outbound deals year-to-date, totaling $100 billion more than the same period in 2017 (“Japan Inc. heads abroad in $180bn deal rush,” December 19, 2018), and mentioned the Takeda-Shire deal.

    “Corporate Japan is focused on buying quality assets,” S&C M&A partner Frank Aquila told MarketWatch. “This is a long-term trend, and we will continue to see Japanese firms engage in this level of activity for a while.”

    Read More
    Stay Updated

    Subscribe to stay current on S&C Insights.

    Our Lawyers

    Our Lawyers

    Francis J. Aquila Headshot Photo
    Francis J. Aquila
    New York
    +1-212-558-4048
    Email
    vCard
    Catherine M. Clarkin Headshot Photo
    Catherine M. Clarkin
    New York
    +1-212-558-4175
    Email
    vCard
    Keiji Hatano Headshot Photo
    Keiji Hatano
    Tokyo
    +81-3-3213-6171
    Email
    vCard
    Nirav N. Mehta Headshot Photo
    Nirav N. Mehta
    Tokyo
    +81-3-3213-6140
    Email
    vCard
    Read More

    Related Practices

    • Asia
    • Capital Markets
    • Healthcare & Life Sciences
    • Mergers & Acquisitions
    Sullivan & Cromwell LLP Logo
    • Twitter icon
    • LinkedIn icon
    • RSS Feed icon
    • Podcasts icon
    • Home
    • Contact Us
    • Information Policy Relating to Cookies
    • Privacy Policy
    • California Privacy Policy
    • Website Notice
    • Attorney Advertising Notice
    © 2025 Sullivan & Cromwell LLP